Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes | Zendy

Mark L. Hartman | Zendy; Arun J. Sanyal | Zendy; Rohit Loomba | Zendy; Jonathan M. Wilson | Zendy; Amir Nikooienejad | Zendy; Ross Bray | Zendy; Chrisanthi A. Karanikas | Zendy; Kevin L. Duffin | Zendy; Deborah Robins | Zendy; Axel Haupt | Zendy

Open Access

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Author(s) -

Mark L. Hartman,

Arun J. Sanyal,

Rohit Loomba,

Jonathan M. Wilson,

Amir Nikooienejad,

Ross Bray,

Chrisanthi A. Karanikas,

Kevin L. Duffin,

Deborah Robins,

Axel Haupt

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc19-1892

Subject(s) - medicine , nonalcoholic steatohepatitis , agonist , diabetes mellitus , type 2 diabetes , glucagon like peptide 1 receptor , endocrinology , receptor , disease , nonalcoholic fatty liver disease , fatty liver

To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research